All In Biotech

Drug Trial Radar · NCT01638910

Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects

A Multi-center, Open, Uncontrolled Phase 3 Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T00658ID Containing Estradiol Valerate and Dienogest in a 28-day Regimen for 13 Cycles in Healthy Female Subjects

Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

955

Actual

Start

Jun 2012

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in healthy female subjects.

Conditions

  • Contraception

Interventions

  • EV/DNG (Qlaira, BAY86-5027)Drug

    Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of unintended pregnanciesTime frame: Up to Cycle 13 (1 Cycle = 28 days)

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Chongqing, China

  • Site not named

    Chongqing, China

  • Site not named

    Chongqing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Tianjin, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Shijiazhuang, Hebei, China

  • Site not named

    Wuhan, Hubei, China

  • Site not named

    Wuhan, Hubei, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Hengyang, Hunan, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Dalian, Liaoning, China

  • Site not named

    Shenyang, Liaoning, China

  • Site not named

    Jinan, Shandong, China

  • Site not named

    Chengdu, Sichuan, China

  • Site not named

    Wenzhou, Zhejiang, China

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Chandigarh, India

  • Site not named

    Karnāl, India

  • Site not named

    New Delhi, India

  • Site not named

    Pune, India

  • Site not named

    Secunderabad, India

  • Site not named

    Pune, Maharashtra, India

  • Site not named

    Kaohsiung City, Taiwan

  • Site not named

    Taichung, Taiwan

  • Site not named

    Taipei, Taiwan

  • Site not named

    Taipei, Taiwan

  • Site not named

    Taoyuan, Taiwan

  • Site not named

    Taipei, Taipei, Taiwan

  • Site not named

    Bangkok, Thailand

  • Site not named

    Chiang Mai, Thailand

  • Site not named

    Bangkok, Thailand, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.